Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 3Neoplasms 2Synovial Cyst 1Spondylosis 1Spondylolisthesis 1Spinal Stenosis 1Radiculopathy 1Pilonidal Sinus 1Pain, Postoperative 1Neoplasms, Second Primary 1Musculoskeletal Diseases 1Malignant Neoplasms of Male Genital Organs 1Intervertebral Disc Displacement 1Intervertebral Disc Degeneration 1Hot Flashes 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Agnosia 1

Interventions

Temozolomide 2Radiosurgery 2Leucovorin 2Irinotecan 2Fluorouracil 2sacubitril and valsartan sodium hydrate drug combination 1icotinib 1dostarlimab 1beta Carotene 1avelumab 1alpha-Tocopherol 1Varenicline 1Tobacco Use Cessation Devices 1Therapeutics 1Thalidomide 1Radiotherapy 1Probiotics 1Panitumumab 1Nicotine Chewing Gum 1Myofascial Release Therapy 1Megestrol Acetate 1Isotretinoin 1Folfox protocol 1Drug Therapy 1Doxycycline 1Docetaxel 1Cryosurgery 1Clonidine 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Second Primary × Clonidine × Clear all
NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡